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ABSTRACT
Background: There is insufficient evidence for the long-
term efficacy and safety of anti-tumour necrosis factor
therapy in patients with ankylosing spondylitis (AS). This
is the first report on the treatment with infliximab over
5 years.
Methods: As part of a multicentre randomised trial, 69
patients with active AS at baseline (BL) have been
continuously treated with infliximab (5 mg/kg i.v. every
6 weeks)—except for a short discontinuation after
3 years (FU1). The primary outcome of this extension was
remission according to the ASsessment in Ankylosing
Spondylitis (ASAS) criteria at the end of year 5 of the
study (FU2).
Results: Of the 43 patients who completed year 3, 42
agreed to continue, 38 of which (90.5%) finished year 5
(55% of 69 initially). Partial clinical remission was
achieved in 13 of 38 patients (34.2%) at FU1 and FU2. At
FU2, the mean Bath Ankylosing Spondylitis Disease
Activity Index (BASDAI) was 2.5¡1.9 (BL:6.4, FU1:2.5).
BASDAI values ,4 were seen in 79% of patients at both,
FU1 and FU2. ASAS 20% and 40% responses were seen
in 32 (84%) and 24 (63%) patients at FU2, respectively.
Most patients classified as non-responders at FU2 were
part-time responders, as all but one patient achieved an
ASAS 20% response at least once within the last 2 years.
Three types of responders were identified. No major side
effects occurred during years 4 and 5 of infliximab
therapy.
Conclusions: Infliximab is safe and efficacious in AS
patients over 5 years. The majority of the patients
remained on treatment and had rather persistent levels of
low disease activity. Different response types could be
identified.
Ankylosing spondylitis (AS), the prototype of the
spondyloarthritides, is a frequent chronic inflam-
matory disease with a prevalence of about 0.5%.1–4
AS affects mostly young patients in the second and
third decade of life.1 Owing to the substantial
burden of disease,5 definite direct and indirect costs
are substantial6–8 and absence from work and work
disability are reportedly threefold increased in AS
patients.8–10
The short-term efficacy of the monoclonal anti-
tumour necrosis factor a (TNF-a) infliximab has
been demonstrated in several studies on patients
with active AS. Recently, we reported on the
impressive clinical efficacy seen in patients
treated with infliximab in a 12-week, double-blind,
placebo-controlled study.11 The clinical efficacy
was maintained in several open-label extension
phases of this study in which patients were treated
continuously with infliximab infusions of 5 mg/kg
every 6 weeks for up to 3 years.12–14 After a short
phase of discontinuation and restart of infliximab
therapy because of clinical relapse patients received
continuous treatment with the TNF blocker.
Magnetic resonance imaging (MRI) examinations
of the same patients showed a significant decrease
of inflammatory spinal lesions in the infliximab
but not in the placebo group.15
Here we report the clinical results of the 5-year
extension of this study.
METHODS
Patients and study protocol
The results of the 12-week, randomised, placebo
controlled phase of the study,11 also of the 1-, 2-
and 3-year extensions have been previously
reported.12 14 16 Briefly, 69 patients with severe
and active AS randomly selected at baseline (BL)
of the initially placebo controlled phase of the
study were assigned to receive infliximab 5 mg/kg
or placebo for 12 weeks. At week 12, patients
initially assigned to placebo switched to infliximab
(5 mg/kg/6 weeks). All patients continued inflix-
imab treatment for 3 years. Disease activity at BL
was assessed by the Bath Ankylosing Spondylitis
Disease Activity Index (BASDAI17). A score of at
least 4 and a spinal pain score of at least 4 (on a
numerical rating scale ranging from 0 to 10) was
required for inclusion. Concomitant disease-mod-
ifying antirheumatic drugs (DMARDs) and oral
corticosteroids were not allowed during the study.
Use of non-steroidal anti-inflammatory drugs
(NSAIDs) was permitted, and dosages of NSAIDs
were allowed to be reduced but not increased
during the study.
After having completed the third year,14 patients
were asked to discontinue infliximab. Thereafter
they were visited regularly to determine the time
to flare.18 A relapse was defined as a BASDAI17value
>4 and physician’s global assessment (PhysGA) >4
according to the ASsessment in Ankylosing
Spondylitis (ASAS) recommendations.19 In the case
of relapse, the patients were reinfused with
infliximab at the same dosage with the same
intervals until the end of year 5 of the study. Most
patients relapsed within 18–24 weeks.18
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The study medication was manufactured by Centocor, Inc.
(Malvern, PA, USA), and was packaged and labelled by Essex
Pharma (Munich, Germany). The local independent ethics
committees approved the original study protocol and all
extension including the one for year 5. All patients who
participated in this extension gave written informed consent.
Assessments
The disease status was assessed by using validated parameters
for disease activity (BASDAI), metrology (Bath AS Metrology
Index (BASMI)20), function (Bath AS Functional Index
(BASFI)21), patient’s (PatGA) and physician’s (PhysGA) global
assessments, and spinal pain (P). All parameters were measured
using a numeric rating scale ranging from 0 to 10.
Peripheral arthritis was assessed by counting the number of
swollen joints out of a total of 64 joints.11 Other reasons for
joint pain, tenderness or swelling had to be excluded clinically
and/or by imaging if necessary. Health-related quality of life
was assessed using the Short Form (SF)-36 questionnaire.22 The
scoring algorithm of the Medical Outcome Trust23 was used to
calculate the SF-36 physical and mental component summary
scores.
The laboratory parameters for inflammation C-reactive
protein (CRP) and erythrocyte sedimentation rate were
measured in all patients. The normal value for CRP is ,6 mg/
dl and for erythrocyte sedimentation rate ,20 mm/1 hour.
The primary outcome parameter was the proportion of
patients with partial clinical remission at the end of the fifth
study year (FU2) in comparison with BL, and to the end of the
third (FU1) study year (the time point before infliximab
discontinuation and readministration). Partial remission was
defined as a score (2 (on a scale of 0–10) in each of the four
ASAS Working Group domains:24 PatGA, NRS-P, function
(represented by the BASFI score), and morning stiffness
(represented by the mean of the two morning stiffness scales
of the BASDAI). At the end of year 5, treatment response was
also assessed by calculating a 50% improvement of the BASDAI,
by a 40% improvement in the ASAS improvement criteria and
by the ‘‘ASAS 5 out of 6’’ criteria.25 To meet the ‘‘ASAS 5 out of
6’’ criteria, a 20% improvement in any five of the following six
domains is required: the four domains used for partial remission,
and in addition spinal mobility (as assessed by the BASMI) and
CRP as acute phase reactant.
Finally, the cut-off for the definition of a low disease activity
state was set at a BASDAI value ,3 units, as previously
proposed26 and definition of high disease activity was set as a
BASDAI>4 units, which was also the inclusion criterion for the
study at BL and at infliximab readministration.11 26
Statistical analysis
For the analysis of the primary outcome parameter, data of the
38 patients who had completed the fifth study year were used.
To compare the mean differences between time points (BL
versus FU1 and FU2), a paired t-test was applied. In the case of
skewed distributions (CRP and erythrocyte sedimentation rate)
the non-parametric Wilcoxon test was used. McNemar test was
applied in the case of proportions. Groups of patients were
compared using the Mann–Whitney test.
RESULTS
The results of the 3-month placebo controlled phase,11 and the
first 3 years of the study have been previously reported.12 14 16
Forty-three of the original 69 patients (62%) completed year 3
and 42 patients agreed to continue with the next phase for
another 2 years. At the end of year 5, four of 42 patients (9.5%)
had withdrawn from the study for various reasons: One patient
withdrew because of planned pregnancy, two other patients
preferred to receive reimbursed medication by her rheumatol-
ogist (fig 3). The remaining patient had experienced a serious
adverse event (see below). Thus, at the end of the fifth year, 38
patients were still in the study (55.1% of 69 patients at BL and
90.5% of 42 patients who entered this extension phase). The
mean age at BL of these 38 completers was 38.7 (8.1) years,
71.1% were male and 94.6% HLA-B27 positive.
Efficacy
Remission
When analysing the proportion of responders, the efficacy of
infliximab at years 4 and 5 of the study appeared to be similar to
the status at the end of year 3 (before infliximab discontinua-
tion). The primary outcome parameter, partial clinical remis-
sion, was achieved by 13 of 38 patients at FU 2 (34.2%), as
compared with 14 of 38 (36.8%) at FU1 (p = NS) (fig 1). Of
interest, seven of 38 patients (18.4%) were in clinical remission
at both time points, 12 weeks after the first infusion of
infliximab and at FU2. This means that, of the 13 patients
who were in clinical remission after 5 years, seven (53.8%) had
already been in clinical remission at 12 weeks (after three
infusions). Similarly, 10 of 38 patients (23.7%) patients were in
clinical remission 24 weeks after the start of infliximab therapy
and also at FU. This implies that the 10 of 13 completers
(76.9%) who had been in remission already after five infliximab
infusions were also in clinical remission after 5 years of therapy.
This was not different for other time points during the first
3 years of the study until the discontinuation of infiximab.
Patient states
When analysing patient states, the efficacy of infliximab also
appeared to persist over 5 years, with similar values for the
clinical assessments at follow-up. After 5 years the mean
BASDAI was 2.5 (1.9) (BL: 6.4, FU1: 2.5) and the mean CRP
was 3.4 (3.9) (BL: 27.7, FU1: 3.2) mg/dl, the mean BASFI was 3.0
(2.4) (BL: 5.4, FU1: 2.9), the mean PatGA 2.7 (2.2) (BL: 7.0, FU1:
2.6) and the mean BASMI was 2.8 (2.1) (BL: 3.6, FU1: 2.6) (all
p,0.05 compared with BL and p = NS between FU1 and FU2).
As shown in fig 2a, the individual parameters of all assessments
Figure 1 Completer analysis of patients in partial remission after
5 years of treatment with infliximab.
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remained at a low level similar to the first and second year of
the study.
After 5 years, a low disease activity state (BASDAI value ,3
units) was reached by 22 of 38 patients (57.9%) and a
BASDAI,4 units was reached by 30 of 38 patients (78.9%). In
comparison, before infliximab discontinuation BASDAI values
,3 units were reached by 20 of 38 patients (52.6%) and BASDAI
valued ,4 units by 24 of 38 patients (63.2%). Most of these
patients (n = 22/30; 73.3%) reached this state of disease activity
at both time points, FU1 and FU2, respectively. The remaining
patients had on average a 60.9% improvement of their initial
BASDAI value and a 62.9% improvement in patient’s global
assessment, and continued to participate in the study.
Baseline parameters had no predictive value to indicate high
disease activity at FU1 or FU2. However, patients with higher
disease activity scores (BASDAI>4) had a tendency to differ
from patients with BASDAI,4 units at FU in disease duration
(18.1 years vs 13.7 years, p = NS) and age (43.4 years vs
37.5 years, p = NS), and were significantly different in their
BASFI values (7.1 units vs 4.9 units, p = 0.001)
Response
An ASAS 40% response was seen in 24 of 38 (63.2%) patients at
FU2, in comparison with 28 of 38 (73.7%) patients at FU1
(fig 2b) (p = 0.29). Similarly, a ‘‘ASAS 5 out of 6’’ response was
achieved in 27 of 38 (71.1%) at FU2 as compared with 29 of 38
(76.3%) patients at FU1 (fig 2b).
An ASAS 20% response was achieved by 36 of 38 patients
(96.7%) at FU1 and by 32 of 38 patients (84.2%) at FU2
(p = 0.13), respectively.
A BASDAI .50% response at FU2 as compared with BL was
found in 25 of 38 patients (65.8%), similar to FU1 with 24 of 38
(63.2%) patients (fig 3).
Responder states over time
In a more detailed analysis of 25 time points over the whole
study period of 5 years (24 weeks after start of infliximab
treatment, FU1 and all visits from the time point of read-
ministration until the end of the end of the study) it was found
that the proportion of ASAS 20 responders showed some
variance over time. However, almost all patients reached an
ASAS 20% response at least once within 5 years (table 1). Only
one patient never had an ASAS 20% response during the entire
study (table 1). The best report of this patient was at 54 weeks
when the improvement in this patient’s global assessment was
50%, in pain 57.1% and in stiffness 10% with only limited
worsening of function by 4.7% was noted.
Importantly, the majority of the 38 patients (n = 22 patients;
58%) showed an ASAS 20% response at all visits between week
24 and 156 and also between week 218 and 256 of the study
(table 1). The ASAS 40% and the ‘‘ASAS 5 out of 6’’
improvement criteria were also reached in most patients at
least once (25 of 38 (65.8%) and 24 of 38 (63.2%) patients,
respectively).
To make distinctions clinically easier we divided the patients
in three groups according to their level and degree of response:
group A patients (n = 10) were in remission at most time points
(>20/25 visits), group B patients (n = 12) had a state of low
disease activity (BASDAI ,3) at most time points (>20/25
visits), and the remainder was attributed to group C (n = 16).
The main difference between A and B+C is mainly the mean age
(31 vs 41 years, respectively) and the mean disease duration (9
vs 17 years). The main difference between groups B and C was
function at baseline (mean BASFI 4.8 vs 6,7, respectively).
Group A differed from B and C mainly in age with 31.2
(6.2) years, 39.5 (7.3) years and 42.9 (6.2) years, respectively
(p = 0.001 between A–B and A–C) and in disease duration with
9.1 (7.0) years, 16.2 (9.4) years and 17.0 (8.6) years, respectively
(p = 0.02 between A–B and A–C). The comparison between
groups B and C showed a difference in function at baseline with
a mean BASFI 4.8 (1.6) vs 6.2 (1.5) respectively, (p = 0.037).
Peripheral manifestations, organ involvement and other symptoms
Enthesitis was observed in 19 of 38 patients at BL (50%) as
compared with seven at FU 1 and FU 2 (18.4%), respectively.
Peripheral arthritis was seen in 12 of 38 patients at BL (31.6%)
as compared with four patients at FU 1 (10.5%) and 3 at FU 2
(7.9%). However, this tendency was at some variance as only
one patient had arthritis at week 54 (2.6%) but there were five
patients with arthritis at week 102 (13.2%) (table 2).
The SF-36 values at FU1 and FU2 remained high (mean scores
42.4 (11.2) and 47.9 (9.9), respectively) as compared with BL
(mean score 29.0 (7.2)) (p = 0.001). The physical sum scale was
29.0 (7.2) at BL, 42.4 (11.2) at the end of year 3, and 41.1 (11.9)
at the end of year 5, respectively. The psychological sum scale
was 42.1 (12.2) at BL, 48.7 (10.2) at the end of year 3, and 47.9
(9.9) at the end of year 5, respectively.
A history of anterior uveitis was reported by 17 of 38 patients
at BL (42%) but only one had had a flare of anterior uveitis
within the last year before inclusion in the study. During year 3
Figure 2 (a) Completer analysis of BASDAI, BASFI and BASMI for all
patients (n = 38) that completed the entire 5-year study period. For the
first 24 weeks of the study (placebo controlled phase), the data are
pooled data from all patients under infliximab treatment (initially-
infliximab and initially-placebo patients). (b) Completer analysis for
BASDAI 50%, ASAS 40% and ‘‘ASAS 5 out of 6’’ response for all patients
(n = 38) that completed the entire study period of 5 years.
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of the study only one patient had a flare of anterior uveitis, and
during years 4 and 5 no patient showed symptoms of anterior
uveitis .
Adverse events
During the fourth and fifth year of the study, 36 of 38 patients
(94.7%) reported at least one adverse event. The most
frequently reported events were common cold (41%), bronchitis
(11%) and increase of liver enzymes (6.5%).
Six of the 43 patients (14%) at FU1 reported serious adverse
events (SAE) during years 4 and 5 of the study. Four of those
were due to hospitalisation for reasons clearly not related to the
study drug, according to the investigator, such as trauma. The
other two SAEs led to discontinuation of the study: one patient
withdrew because of recurrent vaginal infections and the other
patient due to repeated infections of the upper respiratory tract.
According to the investigator, both those SAEs were thought to
be possibly drug related.
DISCUSSION
This study shows that therapy of AS patients is efficacious and
safe over 5 years of almost continuous treatment. There was no
indication of loss of response as indicated by the persistent rate
of remission and low disease activity. As we had tried to
Figure 3 Summary of patient disposition through the entire study period of 5 years.
Table 1 Cross-section analysis of the response to treatment between
week 24 and 156 and also 218 to 256 (25 visits) for all 38 completers



























ASAS 20% 1 (2.6) 0 2 (5.3) 3 (7.9) 10 (26.3) 22 (57.9)
ASAS 40% 3 (7.9) 5 (13.2) 1 (2.6) 4 (10.5) 10 (26.3) 15 (39.5)
Partial
remission
22 (57.9) 2 (5.3) 0 4 (10.5) 6 (15.8) 4 (10.5)
‘‘ASAS 5
out of 6’’*
3 (7.9) 3 (7.9) 3 (7.9) 5 (13.2) 5 (13.2) 19 (50.0)
Numbers are n of patients, numbers in brackets are % of patients.
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discontinue therapy after 3 years without success we believe
that continuous therapy is necessary to achieve a lasting effect
in these patients.
The study shows that the degree of response clearly varies
among patients. About a third of the patients have remained in
a state of remission according to the preliminary ASAS criteria
from the beginning. Another third has developed to a state of
low disease activity as defined by a BASDAI ,3, as recently
proposed,26 also relatively early. However, about 20% of the
patients had a BASDAI .4 after 5 years and, thus, still fulfil the
initial inclusion criteria. In order to clarify how these patients
benefited from anti-TNF therapy we have performed several
subanalyses. One important result is that all but one patient
have fulfilled the ASAS 20 improvement criteria at least once
over time. Another important one is that, on the basis of our
analysis, it seems that there are mainly three types of
responders: type A is in clinical remission early and at most
time points thereafter; type B has a state of low disease activity
at most time points but is not in remission; and type C has
limited improvement but does not fulfil the ASAS 20 improve-
ment criteria at all time points, some even only at a few time
points. This latter subgroup, which is also characterised by a
BASDAI .4 at some time points, is usually older, has longer
disease duration and higher BASFI scores at the time point of
initiation of anti-TNF therapy. This is consistent with our
earlier study on prediction of response.27 Finally, we like to
stress that the doses used in this study has always been the
same. Thus, it cannot be excluded that patients would have had
better outcomes with higher dosages. As loss of response due to
antibody formation has been recently reported28 we have to add
that in this study, after 3 years, only one patient had developed
a significant antibody titre to infliximab,26 this patient has
dropped out in the meantime for other reasons.
A major result of the study is that function as assessed by the
BASFI is largely maintained for the study period of 5 years. In
the natural course of the disease, according to recent reports,29–31
some worsening would have been expected. As function is
known to be affected by both disease activity and structure,31
the question arises which of those plays the major part.
According to our recently published analysis on the radiographs
collected in the study over 4 years32 it is very likely that the
constant suppression of disease activity is essential for the long-
term outcome of active AS patients. It is conceivable that
continuous physical therapy may also be of importance.
Furthermore, there seem to be important differences in
comparison with rheumatoid arthritis33 34 with regard to the
influence of anti-TNF therapy on new bone formation.
Another important observation is that, although infliximab
has been very effective for improving disease activity and other
parameters from the very beginning and lasting over a long
period of time, this response seems to be less impressive with
respect to spinal mobility (as assessed by BASMI) in this study.
There are several explanations for this finding: first, the
assessment tool BASMI due to its structure (scorings on a 0–2
scale, mainly measurement of damage) is known to be not very
sensitive to change. Second, most of the patients involved here
did not have high BASMI values at baseline. This implies that
treatment responses are likely to be even less impressive,
especially as compared with other response parameters, such as
BASDAI, which had to be high for inclusion in anti-TNF
studies. Third, the radiographic damage at baseline, as assessed
by the modified Stoke Ankylosing Spondylitis Spinal Score was
not very low (11.6 units), and actually comparable with
published data from other cohorts (Outcome in Ankylosing
Spondylitis International Study), indicating a significant pro-
portion of patients with structural changes at that time point.
On the other hand, recent results from the same cohort indicate
that there is still some radiographic progression after 4 years of
infliximab therapy.35 Thus, there is some evidence that
infliximab is more effective on disease activity and function
than on structural damage. However, there is need for more
data to draw final conclusions.
Peripheral arthritis was not a major target in this study, as we
had initially concentrated on inflammatory back pain, but 12
patients had reported such symptoms at baseline. At the 5-year
follow-up, there were only three patients who reported signs of
peripheral arthritis. It should be noted that in our study, peripheral
arthritis is documented even if a single finger joint is swollen, and
this may include cases of additional osteoarthritis. Accordingly,
this is likely to cause some hypersensitivity with regard to the
symptom ‘‘peripheral arthritis’’. The numbers of patients with
peripheral arthritis during years 1–3 of the study have been
previously reported, it was generally rather low over the years.12–14
Regarding safety we have reported some serious adverse
events early in the study.11–14 Over 5 years there were no safety
concerns with this limited data set, and this is consistent with
recent data from large registries.36 Thus, it seems that after the
initial years of anti-TNF therapy with infliximab about half of
the initial patient cohort are still being successfully treated. In
addition, the rate of dropouts tended to decrease during the last
2 years.
Taken together, anti-TNF therapy with infliximab is effica-
cious and well tolerated in patients with active AS over 5 years.
Clinical remission can be achieved in many patients with a
convincing safety profile and low rates of drug-related adverse
events. Different types of responders can be differentiated.
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Table 2 Longitudinal analysis of disease status for all 38 completers for assessment of the prevalence of similar clinical status at week 12 and other
follow-up time points of the study
12 weeks (95% CI)
At all time points
of follow-up
At 90% of the time
points (95% CI)
At 80% of the time points
of follow-up (95% CI)
Partial remission 7 (18.4%) (9.2 to 33.4) 3/7 5/7 (71.4%) (35.9 to 91.8) 6/7 (85.7%) (48.7 to 97.4)
BASDAI,3 21 (55.3%) (39.7 to 69.9) 12/21 16/21 (76.2%) (54.9 to 89.4) 19/21 (90.5%) (71.1 to 97.3)
BASFI,3 24 (63.2%) (47.3 to 76.6) 14/24 17/24 (70.8%) (50.8 to 85.1) 17/24 (70.9%) (50.8 to 85.1)
No arthritis 33 (86.8%) (72.7 to 94.2) 24/33 31/33 (93.9%) (80.4 to 98.3) 32/33 (97.0%) (84.7 to 99.5)
No enthesitis 29 (76.3%) (60.8 to 87.0) 14/29 25/29 (86.2%) (69.4 to 94.5) 25/29 (86.2%) (69.4 to 94.5)
No arthritis/enthesitis 28 (73.7%) (58.0 to 85.0) 14/28 22/28 (78.6%) (60.5 to 89.8) 23/28 (82.1%) (64.4 to 92.1)
BASDAI/global assessment ,4 25 (65.8%) (49.9 to 78.8) 12/25 20/25 (80.0%) (60.9 to 91.1) 21/25 (84.0%) (65.3 to 93.6)
CRP (6 mg/l 34 (89.5%) (75.9 to 95.8) 8/34 23/34 (67.6%) (50.8 to 80.9) 27/34 (79.4%) (63.2 to 89.7)
Numbers are n of patients, numbers in brackets are % of patients.
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